Inflammasomes in the Kidney

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

4 Citations (Scopus)

Abstract

Inflammasomes influence a diverse range of kidney disease, including acute and chronic kidney diseases, and those mediated by innate and adaptive immunity. Both IL-18 and in particular IL-1β are validated therapeutic targets in several kidney diseases. In addition to leukocyte-derived inflammasomes, renal tissue cells express functional inflammasome components. Furthermore, a range of endogenous substances that directly activate inflammasomes also mediate kidney injury. Many of the functional studies have focussed on the NLRP3 inflammasome, and there is also evidence for the involvement of other inflammasomes in some conditions. While, at least in some disease, the mechanistic details of the involvement of the inflammasome remain to be elucidated, therapies focussed on inflammasomes and their products have potential in treating kidney disease in the future.

Original languageEnglish
Title of host publicationInflammasomes
Subtitle of host publicationClinical and Therapeutic Implications
EditorsMario Cordero, Elisabet Alcocer-Gomez
Place of PublicationCham, Switzerland
PublisherSpringer
Chapter8
Pages177-210
Number of pages34
ISBN (Electronic)9783319893907
ISBN (Print)9783319893891
DOIs
Publication statusPublished - 1 Jan 2018

Publication series

NameExperientia Supplementum
Volume108
ISSN (Print)1664-431X
ISSN (Electronic)2504-3692

Keywords

  • Acute kidney injury
  • Diabetic nephropathy
  • Glomerulonephritis
  • Inflammasome
  • Interleukin-1β

Cite this